Reactive oxygen species-responsive Pre-PROTAC for tumor-specific protein degradation

Area of Science:

• Chemical Biology
• Drug Discovery
• Molecular Medicine

Background:

• Proteolysis-targeting chimeras (PROTACs) offer a novel therapeutic strategy by inducing targeted protein degradation.
• Controlling the spatial and temporal activation of PROTACs remains a challenge in drug development.
• Endogenous reactive oxygen species (ROS) are implicated in various physiological and pathological processes.

Purpose of the Study:

• To design and evaluate novel ROS-responsive Pre-PROTACs for controlled protein degradation.
• To investigate the efficacy of Pre-PROTAC (7) in degrading the target protein BRD3.
• To establish a method for modulating PROTAC activity using the cellular ROS microenvironment.

Main Methods:

• Synthesis of ROS-responsive Pre-PROTACs incorporating an arylboronic acid leaving group.
• In vitro and cellular assays to assess protein degradation efficiency.
• Correlation analysis between ROS levels and PROTAC activation.

Main Results:

• Successful design and synthesis of ROS-responsive Pre-PROTACs.
• Pre-PROTAC (7) demonstrated efficient and ROS-dependent degradation of BRD3 protein.
• Degradation levels were modulated by varying endogenous ROS concentrations.

Conclusions:

• The developed Pre-PROTACs offer a controllable platform for targeted protein degradation.
• This approach enables precise activation of PROTACs within specific cellular microenvironments.
• The strategy holds promise for developing targeted therapies with enhanced specificity and reduced off-target effects.